-DOCSTART- -X- O
Eight -X- _ O
manufacturing -X- _ O
facilities -X- _ O
participating -X- _ O
in -X- _ O
the -X- _ O
National -X- _ O
Institutes -X- _ O
of -X- _ O
Healthâ€“sponsored -X- _ O
Clinical -X- _ O
Islet -X- _ O
Transplantation -X- _ O
( -X- _ O
CIT -X- _ O
) -X- _ O
Consortium -X- _ O
jointly -X- _ O
developed -X- _ O
and -X- _ O
implemented -X- _ O
a -X- _ O
harmonized -X- _ O
process -X- _ O
for -X- _ O
the -X- _ O
manufacture -X- _ O
of -X- _ O
allogeneic -X- _ B-Intervention
purified -X- _ I-Intervention
human -X- _ I-Intervention
pancreatic -X- _ I-Intervention
islet -X- _ I-Intervention
( -X- _ I-Intervention
PHPI -X- _ I-Intervention
) -X- _ I-Intervention
product -X- _ I-Intervention
evaluated -X- _ O
in -X- _ O
a -X- _ O
phase -X- _ O
3 -X- _ O
trial -X- _ O
in -X- _ O
subjects -X- _ O
with -X- _ O
type -X- _ B-Patient
1 -X- _ I-Patient
diabetes. -X- _ I-Patient
Manufacturing -X- _ O
was -X- _ O
controlled -X- _ O
by -X- _ O
a -X- _ O
common -X- _ O
master -X- _ O
production -X- _ O
batch -X- _ O
record -X- _ O
, -X- _ O
standard -X- _ O
operating -X- _ O
procedures -X- _ O
that -X- _ O
included -X- _ O
acceptance -X- _ O
criteria -X- _ O
for -X- _ O
deceased -X- _ O
donor -X- _ O
organ -X- _ O
pancreata -X- _ O
and -X- _ O
critical -X- _ O
raw -X- _ O
materials -X- _ O
, -X- _ O
PHPI -X- _ O
product -X- _ O
specifications -X- _ O
, -X- _ O
certificate -X- _ O
of -X- _ O
analysis -X- _ O
, -X- _ O
and -X- _ O
test -X- _ O
methods. -X- _ O
The -X- _ O
process -X- _ O
was -X- _ O
compliant -X- _ O
with -X- _ O
Current -X- _ O
Good -X- _ O
Manufacturing -X- _ O
Practices -X- _ O
and -X- _ O
Current -X- _ O
Good -X- _ O
Tissue -X- _ O
Practices. -X- _ O
This -X- _ O
report -X- _ O
describes -X- _ O
the -X- _ O
manufacturing -X- _ O
process -X- _ O
for -X- _ O
75 -X- _ O
PHPI -X- _ O
clinical -X- _ O
lots -X- _ O
and -X- _ O
summarizes -X- _ O
the -X- _ O
results -X- _ O
, -X- _ O
including -X- _ O
lot -X- _ O
release. -X- _ O
The -X- _ O
results -X- _ O
demonstrate -X- _ O
the -X- _ O
feasibility -X- _ B-Outcome
of -X- _ I-Outcome
implementing -X- _ I-Outcome
a -X- _ I-Outcome
harmonized -X- _ I-Outcome
process -X- _ I-Outcome
at -X- _ I-Outcome
multiple -X- _ I-Outcome
facilities -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
manufacture -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
complex -X- _ I-Outcome
cellular -X- _ I-Outcome
product. -X- _ I-Outcome
The -X- _ O
quality -X- _ O
systems -X- _ O
and -X- _ O
regulatory -X- _ O
and -X- _ O
operational -X- _ O
strategies -X- _ O
developed -X- _ O
by -X- _ O
the -X- _ O
CIT -X- _ O
Consortium -X- _ O
yielded -X- _ O
product -X- _ O
lots -X- _ O
that -X- _ O
met -X- _ O
the -X- _ O
prespecified -X- _ O
characteristics -X- _ O
of -X- _ O
safety -X- _ O
, -X- _ O
purity -X- _ O
, -X- _ O
potency -X- _ O
, -X- _ O
and -X- _ O
identity -X- _ O
and -X- _ O
were -X- _ O
successfully -X- _ O
transplanted -X- _ O
into -X- _ O
48 -X- _ O
subjects. -X- _ O
No -X- _ B-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
attributable -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
product -X- _ I-Outcome
and -X- _ I-Outcome
no -X- _ I-Outcome
cases -X- _ I-Outcome
of -X- _ I-Outcome
primary -X- _ I-Outcome
nonfunction -X- _ I-Outcome
were -X- _ I-Outcome
observed -X- _ I-Outcome
. -X- _ O

